Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Idhifa | Enasidenib | Acute myeloid leukemia (AML) | Do not reimburse | Complete | ||
| Nerlynx | Neratinib | ERBB2-positive breast cancer | Do not reimburse | Complete | ||
| Vascepa | icosapent ethyl | Ischemic events in statin-treated patients | Reimburse with clinical criteria and/or conditions | Complete | ||
| Spravato | esketamine hydrochloride | Major depressive disorder (MDD), adults | Do not reimburse | Complete | ||
| Bosulif (RFA) | Bosutinib | Chronic Myeloid Leukemia | N/A | Complete | ||
| Cuvposa | glycopyrrolate | chronic severe drooling, neurologic (pediatric) | Do not reimburse | Complete | ||
| Verkazia | cyclosporine | Severe vernal keratoconjunctivitis, pediatric (≥4 years) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Onstryv | safinamide | Parkinson's disease | Do not reimburse | Complete | ||
| Takhzyro | lanadelumab | Hereditary angioedema, prevention | Reimburse with clinical criteria and/or conditions | Complete | ||
| Benlysta | Belimumab | systemic lupus erythematosus | Do not reimburse | Complete |
Last Updated : May 19, 2024